Levoxin [levofloxacin] tablets – High Potency Broad Spectrum Quinolone


Each film coated scored tablet contains: 500 mg or 250 mg levofloxacin.


Levoxin® (levofloxacin) is a new generation fluoroquinolone with enhanced antimicrobial activity and tissue penetration. It is the levorotatory isomer of ofloxacin and is twice as active as ofloxacin.

Levoxin® is rapidly and completely absorbed after oral administration with a bioavailability reaching up to 99% after oral dose. Its absorption is not affected by food intake. Therefore, it can be administered without regard to food.

Levoxin® has a wide distribution into body tissues and fluids especially into blister fluid, lung tissues, bile, gall bladder, prostate, testis, epididymis, semen and uterine tissues. About 25% of the oral dose is bound to plasma protein.

Levoxin® undergoes minimal hepatic metabolism, and about 90% of the oral dose is excreted as unchanged drug in the urine with an elimination half-life of about 8 hours.

Antimicrobial activity

Levoxin® has a potent bactericidal activity by inhibiting DNA gyrase enzyme which is required for DNA replication, transcription, repair and recombination.

Unlike other quinolones, Levoxin® has an excellent activity against Gram-positive organisms, including streptococcal spp. and anaerobes ; in addition to most Gram-ve organisms and atypical bacteria.

Aerobic Gram positive bacteria

Different species of Staphylococci e.g.,

  • Staph. aureus ( even penicillinase producer or methicillin resistant)
  • Staph. epidermidis
  • Staph. saprophyticus

Different species of Streptococci e.g.,

  • S. pneumoniae (even penicillin resistant species)
  • S. pyogenes
  • S. viridans
  • S. faecalis

Other Gram positive bacteria e.g., 

  • Listeria monocytogenes
  • Mycobacterium tuberculosis

Aerobic Gram negative bacteri

  • Haemophilus influenzae,
  • Morganella morganii.
  • Legionella pneumophilla
  • Providencia spp.
  • Klebsiella pneumoniae
  • Salmonella spp.
  • Escherichia coli
  • Proteus mirabilis
  • Moraxella catarrhalis
  • Shigella spp.
  • Neisseria gonorrhoea
  • Yersinia spp.
  • Pseudomonas aeruginosa
  • Enterobacter spp.

Anaerobic bacteria

  • Bacteroides fragilis
  • Clostridium perfringens

Atypical bacteria

  • Chlamydia pneumoniae
  • Chlamydia trachomatis
  • Mycoplasma pneumoniae


  • Acute maxillary sinusitis
  • Acute bacterial exacerbation of chronic bronchitis
  • Community acquired pneumonia due to typical or atypical bacteria
  • Skin and skin structure infections:  e.g., abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections.
  • Complicated or uncomplicated urinary tract infections, e.g. Upper UTI: e.g., acute pyelonephritis & Lower UTI: e.g., urethritis, cystitis, prostatitis


  • Hypersensitivity to quinolones
  • Patients with a history of epilepsy especially those using nonsteroidal anti-inflammatory drugs
  • During pregnancy and breast feeding
  • Children and adolescent below the age of 18 years


  • Exposure to excessive sunlight may cause photosensitivity and should be avoided.
  • Hypoglycemic reactions may occur rarely in patients using hypoglycemic drugs.

Adverse Reactions

In very rare cases, nausea, diarrhea or sleep disorders may occur.


Acute bacterial exacerbation of chronic bronchitis: 500 mg once daily for 7 days.

Community acquired pneumonia: 500 mg once daily for 7-14 days.

Acute maxillary sinusitis: 500 mg once daily for 10-14 days.

Skin and skin structure infections: 500 mg once daily for 7-10 days

Complicated UTI: 250 mg once daily for 10 days.

Patients with impaired renal function

Infection Creatinine clearance  Initial dose  Subsequent dose
Respiratory tract and skin infections 49-20 ml/min 500 mg. 250 mg once daily.
Respiratory tract and skin infections 19-10 ml/min 500 mg. 250 mg every other day.
Urinary tract
 19-10 ml/min  250 mg  250 mg every other day.

N.B. : 

  • No dose adjustment is needed above these figures.
  • Levoxin® is not removed by dialysis
  • No dose reduction is required in patients with impaired hepatic function.

Drug interactions

Unlike other quinolones, Levoxin® has no significant drug interactions with theophylline, warfarin, digoxin, cyclosporine.

Antacid and metal cations, e.g., Iron, zinc, may interfere with the absorption of Levoxin®, therefore these preparations should be taken 2 hours before or 2 hours after Levoxin® administration.

How Supplied

Levoxin® 500 mg or 250 mg: Strips of 5 scored tablets in packs of 1 strip.

Keep all medicaments out of reach of children

Product of: AMOUN PHARMACEUTICAL CO. El-Obour City, Cairo, Egypt. ATC Code: J01MA12